On June 22, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported the initiation of a randomized Phase 1 trial evaluating TG4070, a novel individualized immunotherapy fully designed and developed in-house by Transgene, in combination with nivolumab in the adjuvant treatment of resected non-small cell lung cancer (NSCLC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TG4070, Transgene’s second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate, reflects the strategic expansion of the myvac platform. Following TG4050, currently being evaluated in the Phase 2 part of a randomized Phase 1/2 trial in head and neck cancer (NTC4183166), TG4070 supports the expansion of the myvac platform into NSCLC while integrating Transgene’s proprietary AI-driven neoantigen selection and cell line manufacturing capabilities. Like TG4050, it leverages Transgene’s clinically validated Modified Vaccinia Ankara (MVA) viral vector, ensuring technological consistency of the myvac platform.
This integrated proprietary ecosystem strengthens Transgene’s control over critical steps of INTV development, with an optimized manufacturing process, aiming at shortening turnaround time (compared to CEF[3] based production), improving scalability and reproducibility, while potentially accelerating development timelines across multiple indications.
"The initiation of this randomized Phase 1 trial of TG4070 represents an important step in Transgene’s strategy to expand the myvac platform beyond TG4050 in head and neck cancer, into additional early-stage solid tumor indications," said Alessandro Riva, MD, Chairman and Chief Executive Officer of Transgene.
"The program reflects the growing integration of Transgene’s proprietary capabilities across AI-driven neoantigen selection through SNIPER and scalable manufacturing infrastructure designed to support broader platform deployment."
SNIPER: Proprietary AI Platform Enabling High-Precision Neoantigen Selection
To support the development of TG4070 and future myvac-derived candidates, Transgene has developed its own in-house, AI-driven bioinformatics tool, SNIPER (Specific Neoantigen Identification and Prediction of Elicited Response). SNIPER is the central component underpinning the neoantigen selection and design of TG4070.
With its multiple integrated computational models, SNIPER is designed to identify and prioritize highly immunogenic neoantigens through a proprietary scoring framework, including tumor-specific expression and antigen presentation intended to optimize candidate selection and support INTV design.
SNIPER highlights Transgene’s strong capabilities in AI-driven neoantigen selection, empowering robust computational development and enabling the scalable development of myvac-derived candidates across additional oncology indications.
In addition, VacDesignR, fully integrated into the myvac platform, is Transgene’s patented in-house computational design engine that optimizes genetic construct for MVA vectors. This integration streamlines design process and significantly improves production reliability and vector quality – key features to achieving reliable, timely and efficient product supply.
Cell-line optimized manufacturing to support broader development
TG4070 is manufactured using a scalable and transposable cell-line based process designed to support broader deployment of INTV candidates while ensuring reliable vaccine supply. Compared with conventional CEF-based manufacturing, the optimized process enables more efficient and automated production, improved lead times and scalability.
Preclinical data demonstrated comparable performance to CEF-based product, supporting continuity with existing clinical data while significantly enhancing scalability.
This manufacturing evolution supports broader deployment of the myvac platform across additional indications and larger patient populations. Transgene also plans to use cell-line based manufacturing in potential future TG4050 clinical trials. TG4050 is currently being evaluated in Phase 2 in head and neck cancer.
TG4070: Expanding the myvac Platform into resected non-small cell lung cancer
The Phase 1 trial will evaluate the safety and tolerability of TG4070 in combination with nivolumab in resected NSCLC patients after neoadjuvant nivolumab plus chemotherapy (EUCT 2025-520946-31-00).
While a perioperative approach with an immunotherapy-based regimen has reshaped the treatment landscape of early-stage NSCLC, approximately 65% of patients do not achieve a major pathological response[4] and remain at high risk of relapse[5].
"Patients with resected non-small cell lung cancer who do not achieve a major pathological response after neoadjuvant chemo-immunotherapy remain at significant risk of relapse. TG4070 represents a compelling approach in this setting, as individualized neoantigen therapeutic vaccines can induce highly specific and durable anti-tumor immune responses. In combination with an immune checkpoint inhibitor such as nivolumab, this strategy has the potential to further enhance T-cell activity and improve outcomes in this high-risk population," said Nicolas Girard, MD, PhD, Professor of Thoracic Oncology at Curie Institute and Principal Investigator of the TG4070 trial.
Transgene will host a webcast on June 29, 2026, at 3:00 p.m. CET / 9:00 a.m. ET (in English).
During this live event, Transgene’s team, including Alessandro Riva, Chairman and CEO, and Prof. Nicolas Girard, MD, PhD, (Institut Curie), will discuss the expansion of the myvac platform, the medical need for early-stage NSCLC patients and the potential benefit of TG4070 in this indication.
(Press release, Transgene, JUN 22, 2026, View Source [SID1234668817])